NewAmsterdam Pharma Company NV (NASDAQ: NAMS) is -7.39% lower on its value in year-to-date trading and has touched a low of $15.19 and a high of $27.29 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NAMS stock was last observed hovering at around $23.50 in the last trading session, with the day’s gains setting it 0.3%.
Currently trading at $23.80, the stock is 18.09% and 6.35% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.37 million and changing 1.28% at the moment leaves the stock 20.05% off its SMA200. NAMS registered 6.87% gain for a year compared to 6-month gain of 48.56%.
The stock witnessed a 13.06% loss in the last 1 month and extending the period to 3 months gives it a 19.12%, and is 13.33% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.70% over the week and 7.18% over the month.
NewAmsterdam Pharma Company NV (NAMS) has around 68 employees, a market worth around $2.61B and $45.56M in sales. Profit margin for the company is -530.25%. Distance from 52-week low is 56.68% and -12.79% from its 52-week high. The company has generated returns on investments over the last 12 months (-31.89%).
The EPS is expected to grow by 29.13% this year.
NewAmsterdam Pharma Company NV (NAMS) Top Institutional Holders
The shares outstanding are 108.06M, and float is at 56.66M with Short Float at 5.14%.
The top institutional shareholder in the company is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with over 12.23 million shares valued at $234.88 million. The investor’s holdings represent 12.9097% of the NAMS Shares outstanding. As of 2024-06-30, the second largest holder is FCPM III SERVICES B.V. with 11.83 million shares valued at $227.28 million to account for 12.4921 of the shares outstanding. The other top investors are BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC which holds 10.47 million shares representing 11.0587% and valued at over $201.2 million, while RA CAPITAL MANAGEMENT, L.P. holds 8.5143 of the shares totaling 8.06 million with a market value of $154.91 million.
NewAmsterdam Pharma Company NV (NAMS) Insider Activity
The most recent transaction is an insider purchase by Topper James N, the company’s Director. SEC filings show that Topper James N bought 4,005 shares of the company’s common stock on Mar 04 ’25 at a price of $21.02 per share for a total of $84203.0. Following the purchase, the insider now owns 3.01 million shares.
NewAmsterdam Pharma Company NV disclosed in a document filed with the SEC on Mar 04 ’25 that Kooij Louise Frederika (Chief Accounting Officer) sold a total of 150,000 shares of the company’s common stock. The trade occurred on Mar 04 ’25 and was made at $20.37 per share for $3.06 million. Following the transaction, the insider now directly holds 15000.0 shares of the NAMS stock.
Still, SEC filings show that on Mar 04 ’25, Kooij Louise Frederika (Officer) Proposed Sale 150,000 shares at an average price of $20.27 for $3.04 million. The insider now directly holds shares of NewAmsterdam Pharma Company NV (NAMS).
